Old Web
English
Sign In
Acemap
>
Paper
>
Phase III study comparing bevacizumab plus erlotinib (BE) to erlotinib(E) for NSCLC with EGFR mutations (NEJ026)
Phase III study comparing bevacizumab plus erlotinib (BE) to erlotinib(E) for NSCLC with EGFR mutations (NEJ026)
2018
Fukuhara Tatsuro
Furuya Naoki
Saito Haruhiro
Sugawara Shunichi
Iwasawa Shunichiro
Tsunezuka Yoshio
Yamaguchi Ou
Okada Morihito
Yoshimori Kozo
Nakachi Ichiro
Hagiwara Koichi
Nukiwa Toshihiro
Morita Satoshi
Kobayashi Kunihiko
Maemondo Makoto
Keywords:
egfr mutation
Internal medicine
Medicine
Erlotinib
Oncology
thesaurus
Bevacizumab
Correction
Source
Cite
Save
Machine Reading By IdeaReader
0
References
0
Citations
NaN
KQI
[]